These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 29426727)

  • 1. Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
    Hazendonk HCAM; van Moort I; Mathôt RAA; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH;
    Blood Rev; 2018 Jul; 32(4):265-271. PubMed ID: 29426727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How do we optimally utilize factor concentrates in persons with hemophilia?
    Lim MY
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):206-214. PubMed ID: 34889393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges.
    Trinchero A; Sholzberg M; Matino D
    Hamostaseologie; 2020 Aug; 40(3):311-321. PubMed ID: 32726826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.
    Preijers T; Schütte LM; Kruip MJHA; Cnossen MH; Leebeek FWG; van Hest RM; Mathôt RAA
    Ther Drug Monit; 2019 Apr; 41(2):192-212. PubMed ID: 30883513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in developing specific therapies for haemophilia.
    Ling G; Nathwani AC; Tuddenham EGD
    Br J Haematol; 2018 Apr; 181(2):161-172. PubMed ID: 29359795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New viewpoints in the treatment of hemophilia].
    Göbel U
    Dtsch Med Wochenschr; 1973 Sep; 98(39):1814-6. PubMed ID: 4583442
    [No Abstract]   [Full Text] [Related]  

  • 8. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapies for hemophilia.
    Pipe SW
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):650-656. PubMed ID: 27913542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hemophilia in developing countries.
    Kashyap R; Choudhry VP
    Indian J Pediatr; 2001 Feb; 68(2):151-7. PubMed ID: 11284184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemophilia B: Where are we now and what does the future hold?
    Dolan G; Benson G; Duffy A; Hermans C; Jiménez-Yuste V; Lambert T; Ljung R; Morfini M; Zupančić Šalek S
    Blood Rev; 2018 Jan; 32(1):52-60. PubMed ID: 28826659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I manage patients with inherited haemophilia A and B and factor inhibitors.
    Ljung RCR
    Br J Haematol; 2018 Feb; 180(4):501-510. PubMed ID: 29270992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific therapy in hemophilia.
    Hutaff LW
    N C Med J; 1973 Mar; 34(3):193-6. PubMed ID: 4510809
    [No Abstract]   [Full Text] [Related]  

  • 17. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII/factor IX prophylaxis for severe hemophilia.
    Carcao M; Srivastava A
    Semin Hematol; 2016 Jan; 53(1):3-9. PubMed ID: 26805901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Substitution treatment in hemophilia. Critical measures and complications].
    Schimpf K
    Wien Med Wochenschr; 1977 Jun; 127(11):329-37. PubMed ID: 878496
    [No Abstract]   [Full Text] [Related]  

  • 20. Switching patients in the age of long-acting recombinant products?
    Escobar M; Santagostino E; Mancuso ME; Coppens M; Balasa V; Taylor JA; Iorio A; Negrier C
    Expert Rev Hematol; 2019; 12(sup1):1-13. PubMed ID: 31282771
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.